The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

IX.a

Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)

Publications

Thapa B, Khalid S, Vakili R, Ui J, Misbah S

Nivolumab-Associated Guillain-Barre Syndrome in a Patient With Non-Small-Cell Lung Cancer.

American journal of therapeutics 2018 Nov/Dec;25;e761-e763 — 2018 Nov/Dec — e761-e763

Yoshioka M, Kambe N, Yamamoto Y, Suehiro K, Matsue H

Case of respiratory discomfort due to myositis after administration of nivolumab.

The Journal of dermatology 2015 Oct;42;1008-9 — 2015 Oct — 1008-9